Clinical events | Associate factors | References |
---|---|---|
Hepatitis B e antigen (HBeAg) seroconversion | Host factors | Â |
 | Puberty onset | |
 | Steroid 5-alpha reductase type II | [19] |
 | Dehydroepiandrosterone sulphate | [26] |
 | Human leukocyte antigen (HLA)-B61 and HLA-DQB1*0503 | [39] |
 | Interleukin-10 and 12 | [42] |
 | Toll-like receptor-5 and -9 | [43] |
 | Furin | |
 | Program death 1 and program death ligand-1 pathway | |
 | Virus factors |  |
 | HBV Genotype | |
 | HBV mutant strains (core-promotor, precore, core gene) | |
 | HBV viral load | [26] |
HBV viral titer decrement | Host factors | Â |
 | Puberty onset | [19] |
 | Dehydroepiandrosterone sulphate | [26] |
 | Virus factors |  |
 | HBV mutant strains (core-promotor, precore, core gene) | |
Hepatitis B surface antigen (HBsAg) seroclearance/seroconversion | Host factors | Â |
 | Dehydroepiandrosterone sulphate | [26] |
 | Gut microbiota | [47] |
 | Menarche onset (in females) | [20] |
 | HLA (DRB1*1301-02, DR2, DR7, DR*0406, B*4001, DPA1 and DPB1) | |
 | Interleukin-10 and 12 | [45] |
 | Tumor necrosis factor alpha | [41] |
 | Toll-like receptor-4 | |
 | Program death 1 and program death ligand-1 pathway | [46, 48, 70] |
 | Breakthrough of immune tolerance | [45] |
 | HBeAg seroconversion at childhood | [45] |
 | Virus factors |  |
 | HBV viral load | [45] |
 | HBsAg titer | [45] |
HBeAg-negative hepatitis | HBeAg seroconversion age | |
 | HBV mutant |